This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)
by Zacks Equity Research
Novartis (NVS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
5 Low-Leverage Stocks to Buy Amid the Focus on Inflation Data
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You can buy JHG, CCB, NVS, APOG and IDCC.
Top Stock Reports for Netflix, Salesforce & Cisco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc. (NFLX), Salesforce, Inc. (CRM) and Cisco Systems, Inc. (CSCO), as well as a micro-cap stock, BK Technologies Corporation (BKTI).
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
by Zacks Equity Research
IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
by Zacks Equity Research
Catalyst stock gains on strong third-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales. Management raises sales guidance.
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
by Zacks Equity Research
PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
Acadia's Q3 Earnings Beat, Nuplazid & Daybue Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
by Zacks Equity Research
Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
by Zacks Equity Research
RARE reports encouraging third-quarter results, beating earnings and revenue estimates. Product sales increase year over year.
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
by Zacks Equity Research
EDIT reports mixed third-quarter 2024 results as earnings beat expectations while revenues miss the same.
Is Novartis (NVS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and Novartis (NVS) have performed compared to their sector so far this year.
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
by Zacks Equity Research
ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
by Kinjel Shah
LLY, MRK, PFE, ABBV and NVS announce report third-quarter results.
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
by Zacks Equity Research
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
by Zacks Equity Research
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
by Zacks Equity Research
Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
by Zacks Equity Research
Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
by Zacks Equity Research
Eli Lilly misses third-quarter estimates for earnings and sales. Mounjaro and Zepbound sales also miss estimates. Stock declines 11%.
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
by Zacks Equity Research
BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.
ITCI Q3 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
by Zacks Equity Research
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.